Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Blood (2006) 108 (5): 1469–1477.

https://doi.org/10.1182/blood-2005-11-4386

Published: 2006

Journal Articles

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Heike Pfeifer, MD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Aristoteles Giagounidis, MD, Michael Stelljes, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, Barbara Wassmann, MD

Blood (2005) 106 (11): 1824.

https://doi.org/10.1182/blood.V106.11.1824.1824

Published: 2005

Journal Articles

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Heike Pfeifer, MD, Barbara Wassmann, MD, Anni Pavlova, MD, Martin Mueller, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Johannes Oldenburg, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2005) 106 (11): 147.

https://doi.org/10.1182/blood.V106.11.147.147

Published: 2005

Journal Articles

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Barbara Wassmann, Heike Pfeifer, Michael Stadler, Martin Bornhaüser, Gesine Bug, Urban J. Scheuring, Patrick Brück, Matthias Stelljes, Rainer Schwerdtfeger, Nadezda Basara, Jolanta Perz, Donald Bunjes, Georg Ledderose, Rolf Mahlberg, Anja Binckebanck, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2005) 106 (2): 458–463.

https://doi.org/10.1182/blood-2004-05-1746

Published: 2005

Includes: Supplemental data

Journal Articles

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Thomas Kindler, Frank Breitenbuecher, Stefan Kasper, Eli Estey, Francis Giles, Eric Feldman, Gerhard Ehninger, Gary Schiller, Virginia Klimek, Stephen D. Nimer, Alois Gratwohl, Chuna Ram Choudhary, Constan Mueller-Tidow, Hubert Serve, Harald Gschaidmeier, Pamela S. Cohen, Christoph Huber, Thomas Fischer

Blood (2005) 105 (1): 335–340.

https://doi.org/10.1182/blood-2004-02-0660

Published: 2005

Journal Articles

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

Oliver G. Ottmann, MD, Barbara Wassmann, MD, Heike Pfeifer, MD, Nicola Goekbuget, MD, Gesine Bug, MD, Patrick Brueck, MD, Anja Binckebanck, Harald Gschaidmeier, MD, Dieter Hoelzer, MD

Blood (2004) 104 (11): 685.

https://doi.org/10.1182/blood.V104.11.685.685

Published: 2004

Journal Articles

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Harald Gschaidmeier, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2004) 104 (11): 2929.

https://doi.org/10.1182/blood.V104.11.2929.2929

Published: 2004

Journal Articles

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Joachim Beck, Georg Hess, Birgit Weinkauf, Justus Duyster, Christian Peschel, Charles J. Kirkpatrick, Matthias Theobald, Harald Gschaidmeier, Christoph Huber, Thomas Fischer

Blood (2004) 103 (10): 3644–3654.

https://doi.org/10.1182/blood-2003-06-2071

Published: 2004

Journal Articles

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Barbara Wassmann, Heike Pfeifer, Urban J. Scheuring, Anja Binckebanck, Nicola Gökbuget, Johannes Atta, Patrick Brück, Harald Rieder, Claudia Schoch, Lothar Leimer, Rainer Schwerdtfeger, Gerhard Ehninger, Thomas Lipp, Jolanta Perz, Matthias Stelljes, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2004) 103 (4): 1495–1498.

https://doi.org/10.1182/blood-2003-01-0154

Published: 2004

Journal Articles

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia

Wolf-Karsten Hofmann, Martina Komor, Barbara Wassmann, Letetia C. Jones, Harald Gschaidmeier, Dieter Hoelzer, H. Phillip Koeffler, Oliver G. Ottmann

Blood (2003) 102 (2): 659–661.

https://doi.org/10.1182/blood-2002-06-1756

Published: 2003

Journal Articles

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML

Thomas Kindler, Frank Breitenbuecher, Andreas Marx, Georg Hess, Harald Gschaidmeier, Heinold Gamm, Charles J. Kirkpatrick, Christoph Huber, Thomas Fischer

Blood (2003) 101 (8): 2960–2962.

https://doi.org/10.1182/blood-2002-05-1469

Published: 2003

Journal Articles

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Andreas Burchert, Stefan Wölfl, Manuel Schmidt, Cornelia Brendel, Barbara Denecke, Dali Cai, Larissa Odyvanova, Tanja Lahaye, Martin C. Müller, Thomas Berg, Harald Gschaidmeier, Burghardt Wittig, Rüdiger Hehlmann, Andreas Hochhaus, Andreas Neubauer

Blood (2003) 101 (1): 259–264.

https://doi.org/10.1182/blood-2002-02-0659

Published: 2003

Journal Articles

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Urban J. Scheuring, Heike Pfeifer, Barbara Wassmann, Patrick Brück, Johannes Atta, Eduard K. Petershofen, Brigitte Gehrke, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann

Blood (2003) 101 (1): 85–90.

https://doi.org/10.1182/blood-2002-02-0360

Published: 2003

Journal Articles

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Tim H. Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Alexandra Wahl, Peter Paschka, Sebastian Kreil, Tanja Lahaye, Ute Berger, Harald Gschaidmeier, Carsten Bokemeyer, Rüdiger Hehlmann, Klaus Dietz, Peter M. Lansdorp, Lothar Kanz, Andreas Hochhaus

Blood (2003) 101 (1): 375.

https://doi.org/10.1182/blood-2002-08-2557

Published: 2003

Journal Articles

Ph + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

Wolf-K. Hofmann, Letetia C. Jones, Nathan A. Lemp, Sven de Vos, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann, H. Phillip Koeffler

Blood (2002) 99 (5): 1860–1862.

https://doi.org/10.1182/blood.V99.5.1860

Published: 2002

NARROW

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Early molecular response to posttransplantation imatinib determines outcome in MRD + Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

A Multicenter Phase I/II Trial of the Combination of Imatinib Mesylate with Mitoxantrone/Etoposide and Cytarabine in Patients with CML in Myeloid Blast Crisis: A Trend to a Longer Survival in Patients Receiving More Aggressive Treatment Schedules.

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Ph + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only